CAR T-Cell Therapy Shows Promise in Advanced Kidney Cancer
ORLANDO — An off-the-shelf, allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD70 demonstrated antitumor activity in patients with advanced clear cell renal cell carcinoma (RCC), according to results from the phase I TRAVERSE trial. Three of 18 efficacy-evaluable patients (17%) responded to treatment with ALLO-316, and the disease control rate (DCR) reached 89%, reported […]